Oral Colon-Targeted Lipid Nanoparticles Enhance Upadacitinib Delivery and Efficacy in a Murine Model of Ulcerative Colitis.

While the difference did not reach statistical significance ( p = 0.1083), UPA-nLNP-treated mice demonstrated a consistent trend toward improved body weight recovery throughout the treatment period, suggesting a potential therapeutic benefit over free UPA in promoting clinical improvement during colitis recovery ( Figure 5 B).

also in 111,027 other papers